VANCOUVER & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership.
“On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team,” said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. “His experience across a range of diverse strategic roles will be highly instrumental as we continue to advance our commercial launch of ZUNVEYL and advance our sublingual program for mild-to-moderate Alzheimer’s Disease. Our board looks forward to working with Robert and leveraging his unique expertise.”
Dr. Wills joins the Board with over four decades of experience as a leader in the pharmaceutical industry. Dr. Wills serves as Chairman of the Board of Milestone Pharmaceuticals, Inc. (Nasdaq: MIST), and serves as a board member at Parion Sciences, Inc. and Oncternal Therapeutics (Nasdaq: ONCT). Dr. Wills previously served as the Chairman of the Board of CymaBay Therapeutics (Nasdaq: CBAY) prior to the acquisition by Gilead Sciences, Inc. in March 2024, and served as Executive Chairman of GTx, Inc. from 2015-2019. Prior to that he spent over 25 years at Johnson & Johnson. His roles included Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson and as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. Dr. Wills holds a B.S. in Biochemistry and a M.S. in Pharmaceutics from the University of Wisconsin and a Ph.D. in Pharmaceutics from the University of Texas.
Alpha Cognition today also announces that John Havens has notified the Company of his intention to not seek re-election to the Company’s Board of Directors for 2025 forward. Mr. Havens joined the Alpha Cognition Board of Directors in 2018 and served as a member of the Audit and Governance Committees. During his tenure, he has contributed his private and emerging company expertise to provide guidance and valuable insights to drive the company’s advancement to the public markets and to advance its pipeline to an FDA approved product.
The Board of Directors and the Company’s management team would like to thank John for his valuable contributions to Alpha Cognition and wish him well with his current and future business ventures.
The Company will immediately begin a search for a new independent board member to replace Mr. Havens.
About ZUNVEYL
ZUNVEYL (benzgalantamine) is a twice-daily treatment designed to address the cognitive symptoms of mild-to-moderate Alzheimer’s disease. By enhancing cholinergic function in the brain, ZUNVEYL supports memory, learning, and overall cognitive function, offering a meaningful improvement for patients and their caregivers.
Targeted for the long-term care market, ZUNVEYL is uniquely positioned to address the needs of a growing patient population in a segment valued at $2 billion annually in the United States. Alpha Cognition is committed to ensuring ZUNVEYL is accessible to patients and caregivers, supported by robust market access strategies and a dedicated commercial team.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
For more information, please visit www.alphacognition.com.
